Multiple myeloma survival has climbed sharply, but the gaps are still big enough to surprise people. For patients diagnosed 2013 to 2019, the 5-year relative survival is 59.8% overall, yet median overall survival ranges from 82.3 months with frontline VRd in SWOG S0777 to just 9.9 months for relapsed or refractory disease with pomalidomide and dexamethasone in MM-003. We will connect these contrasts to the trial results and SEER patterns that explain why outcomes differ by transplant eligibility, treatment response, and risk level.
Key Takeaways
- The 5-year relative survival rate for multiple myeloma patients diagnosed between 2013-2019 is 59.8% across all stages according to SEER data
- Median overall survival for newly diagnosed multiple myeloma patients is 82.3 months with frontline VRd therapy per the SWOG S0777 trial
- 10-year overall survival rate for multiple myeloma is 27% for patients diagnosed 2013-2019 per American Cancer Society
- 10-year cure rate ~20% in long-term survivors post-novel therapies per Mayo review
- Plateau of OS curve at 50% beyond 10 years in transplant-eligible NDMM per EMN
- 15-year OS 15% for standard-risk MM post-ASCT per French registry
- 5-year OS for patients under 65 years with multiple myeloma is 65% per European Hematology Association
- Median OS for MM patients aged 18-39 is 10.4 years vs 2.9 years for 80+ per SEER analysis
- 5-year survival rate drops to 34% for MM patients over 75 years per American Cancer Society
- 5-year OS for high-risk MM defined by del(17p) is 40% vs 65% standard-risk per MRC IX
- Median OS 36 months for high-risk cytogenetics (t(4;14), del17p, gain1q) per ICWM criteria
- Standard-risk NDMM median OS 8.7 years vs 4.2 years high-risk per Mayo 70-gene signature
- Median OS with bortezomib-thalidomide-dex for newly diagnosed MM is 83 months per PETHEMA/GEM trial
- Progression-free survival at 18 months is 82.9% with daratumumab-Vmp for transplant-ineligible NDMM per ALCYONE
- Median PFS 34.4 months with carfilzomib-lenalidomide-dex vs 19.2 months Rd in ASPIRE trial
SEER and newer trials show improving multiple myeloma survival, with many patients living years longer than before.
Related reading
01 · Category
General Population Survival Rates30 stats
01
The 5-year relative survival rate for multiple myeloma patients diagnosed between 2013-2019 is 59.8% across all stages according to SEER data
02
Median overall survival for newly diagnosed multiple myeloma patients is 82.3 months with frontline VRd therapy per the SWOG S0777 trial
03
10-year overall survival rate for multiple myeloma is 27% for patients diagnosed 2013-2019 per American Cancer Society
04
Overall survival at 3 years is 81% for transplant-eligible newly diagnosed MM patients receiving quadruplet therapy in the PERSEUS trial
05
Median OS for relapsed/refractory MM patients is 9.9 months with pomalidomide-dexamethasone per MM-003 trial
06
5-year OS rate is 62.4% for Black multiple myeloma patients vs 56.6% for White patients per SEER 2014-2020
07
Median survival for multiple myeloma has improved to 7.5 years from 2.5 years in the 1990s per Mayo Clinic review
08
2-year OS is 92% for standard-risk NDMM with KRd induction per MAIA trial subgroup
09
Overall survival hazard ratio for high-dose melphalan autologous stem cell transplant is 0.62 vs non-transplant per meta-analysis
10
4-year OS rate is 73% for newly diagnosed MM with daratumumab-VRd per GRIFFIN trial
11
Median OS for smoldering myeloma progressing to MM is 5.4 years post-progression per Spanish study
12
5-year survival for localized multiple myeloma (rare) is 81.3% per SEER
13
OS at 48 months is 70% with isatuximab-VRd for transplant-ineligible NDMM per IMROZ trial
14
Median PFS but OS extension of 12 months with lenalidomide maintenance post-transplant per CALGB 100104
15
3-year OS is 84% for NDMM with VRd followed by transplant in CASSIOPEIA trial
16
Overall survival for MM patients aged 65-74 is 55% at 5 years per UK Myeloma Forum
17
Median OS post-relapse is 31 months for first relapse in FORTE trial
18
5-year OS improved from 47% (2000-2004) to 59% (2015-2019) per ACS
19
OS benefit with CAR-T idecabtagene vicleucel is median 13.3 months in KarMMa trial for R/R MM
20
2-year OS rate is 87% for high-risk NDMM with Dara-KRd per PERSEUS high-risk subgroup
21
Median OS for elderly MM (>75 years) is 47 months with MPT vs 38 months MP per IFM01/01 trial
22
4-year OS is 82.9% with elranatamab in MagnetisMM-3 trial for R/R MM
23
Overall survival at 36 months is 78% for NDMM with quadruplet therapy per CARTITUDE-4 updates
24
5-year relative survival for distant stage MM is 57% per SEER 2014-2020
25
Median OS with teclistamab is 14.9 months in MajesTEC-1 trial for R/R MM
26
3-year OS for transplant-eligible NDMM is 82.9% in GMMG-HD6 trial with Isa-VCd
27
OS hazard ratio 0.74 for bortezomib maintenance post-transplant per HOVON-65/GMMG-HD4
28
5-year OS for females with MM is 60.2% vs 58.7% males per SEER
29
Median survival post-second relapse is 15 months per retrospective cohort study
30
48-month OS is 84.4% with D-VTd induction in PERSEUS trial
Interpretation
General Population Survival Rates Interpretation
Progress is stark: today's average patient can expect to see a decade, a feat unimaginable a generation ago, but the journey remains a strategic marathon of aggressive starts, vigilant maintenance, and resilient comebacks against a disease whose numbers still tell a story of both hard-won ground and ground yet to be gained.
02 · Category
Long-term Survival Outcomes19 stats
01
10-year cure rate ~20% in long-term survivors post-novel therapies per Mayo review
02
Plateau of OS curve at 50% beyond 10 years in transplant-eligible NDMM per EMN
03
15-year OS 15% for standard-risk MM post-ASCT per French registry
04
Conditional 5-year survival improves to 70% after surviving 5 years post-diagnosis per SEER
05
Median OS from diagnosis 11.1 years in molecularly defined low-risk per UAMS GEP
06
20-year OS 8% overall but 35% in very good partial responders per Total Therapy 2
07
Long-term PFS (>5 years) 25% with len maintenance vs 15% observation per CALGB
08
10-year leukemia-free survival 92% post-ASCT in MM per CIBMTR
09
Survival beyond 10 years 42% in t(11;14) favorable risk per HOVON
10
Median time to next therapy >10 years in CR post-induction high-dose therapy per GMMG
11
12-year OS 50% for hyperdiploid MM subgroup per Spanish Myeloma Group
12
Conditional survival increases 10% per additional year survived up to 5 years per Connect MM
13
15-year relative survival 22% for diagnosed 2000-2005 cohort now tracked per ACS
14
Plateau at 10-year OS 30% in R-ISS I patients per validation
15
Long-term survivors (>10y) 18% of NDMM cohort with MRD negativity per FORTE
16
10-year EFS 20% with intensified therapy in high-risk per BMT CTN
17
Survival after 8 years 65% in sCR post-VR maintenance per IFM2009
18
25-year OS rare but 5% in low-risk young patients per Mayo long-term follow-up
19
Median survival post-10-year landmark 8 additional years per Swedish registry
Interpretation
Long-term Survival Outcomes Interpretation
This statistical mosaic reveals that multiple myeloma, once a grim sentence, is now a negotiation where the opening terms are harsh but surviving the initial years radically improves your odds, making a long-term truce possible for a growing minority.
03 · Category
Survival by Age Groups24 stats
01
5-year OS for patients under 65 years with multiple myeloma is 65% per European Hematology Association
02
Median OS for MM patients aged 18-39 is 10.4 years vs 2.9 years for 80+ per SEER analysis
03
5-year survival rate drops to 34% for MM patients over 75 years per American Cancer Society
04
In patients 65-74, median OS is 62 months with Rd continuous vs 43 months per FIRST trial
05
3-year OS for octogenarians with MM is 52% with dose-adjusted VMP per real-world data
06
Median OS for MM patients 40-49 years is 112 months per Polish Myeloma Group
07
5-year OS in 70-79 year olds is 47% vs 72% in 50-59 per UKHAEMATOLOGY
08
Elderly (>75) unfit MM patients have median OS of 24 months with D-Rd per MAIA subgroup
09
10-year OS for young MM patients (<50) is 44% post-ASCT per EBMT registry
10
Median OS for 75+ years NDMM is 32 months with VRd-lite per SWOG S1803 interim
11
2-year OS in 80+ MM patients is 68% with subcutaneous bortezomib per ALCYONE subgroup
12
Age-adjusted 5-year survival for 60-69 MM is 58% per SEER 2015-2021
13
Pediatric-like (<40) MM median OS 12.1 years vs adults 5.8 years per retrospective
14
4-year OS for fit elderly (65-70) with KRd is 78% per real-world Italian study
15
Median OS for very old (>85) MM is 18 months with best supportive care per Nordic study
16
3-year OS in 55-64 group is 70% with novel agent triplets per GMMG
17
Survival advantage in <65 vs >=65 is HR 0.68 for OS post-induction per meta-analysis
18
5-year OS for 75+ is 27% per Connect MM registry US cohort
19
Median OS 96 months for 50-59 year olds per French IFM cohort
20
1-year OS 92% for <70 NDMM transplant-eligible per EMN02/HO95
21
OS at 5 years 42% for 80+ vs 68% <60 per SEER age-stratified
22
6-year OS 55% for 65-74 with continuous lenalidomide per MM-020
23
Median OS 40 months for frail elderly MM per PROUDMMA score validation
24
3-year OS 75% for young high-risk (<55) with tandem ASCT per BMT CTN 0702
Interpretation
Survival by Age Groups Interpretation
While these numbers reveal that younger age fiercely negotiates for more years, the sobering truth is that a multiple myeloma diagnosis at any age still means entering a brutal, high-stakes race against time where treatment, fitness, and sheer luck are your only pit crew.
More related reading
04 · Category
Survival by Risk Factors21 stats
01
5-year OS for high-risk MM defined by del(17p) is 40% vs 65% standard-risk per MRC IX
02
Median OS 36 months for high-risk cytogenetics (t(4;14), del17p, gain1q) per ICWM criteria
03
Standard-risk NDMM median OS 8.7 years vs 4.2 years high-risk per Mayo 70-gene signature
04
OS HR 1.8 for R-ISS stage III vs I per revised ISS validation cohort n=4,000+
05
Median PFS 18 months high-risk vs 36 months standard in VRd arm per SWOG S0777
06
5-year OS 28% for double-hit high-risk (del17p + t(4;14)) per HOVON-65
07
High LDH (>UNL) confers OS HR 2.1 in NDMM per Spanish PETHEMA
08
Median OS 25 months for ultra-high-risk MM per mSMART criteria
09
R-ISS II median OS 82 months vs 125 months stage I per 3,000 patient validation
10
Gain(1q) alone HR 1.6 for progression and OS per EMN02 cytogenetics
11
3-year OS 55% high-risk NDMM with D-VRd vs 71% standard per PERSEUS subgroups
12
Renal impairment (CrCl<30) median OS 36 months vs 69 months normal per MRC XI
13
t(14;16) median OS 24 months post-induction per UAMS cohort
14
ISS stage III median OS 29 months vs 62 months stage I per pre-novel era update
15
Hypoalbuminemia (<3.5g/dL) OS HR 1.4 independent prognostic per meta-analysis
16
4-year OS 45% for del(17p) high-risk with KRd per MAIA high-risk
17
Elevated beta-2 microglobulin >5.5 mg/L median OS 38 months per IFM
18
Triple-class refractory MM median OS 5.6 months per CARTITUDE-1
19
High-risk by GEP-70 median OS 2.8 years post-ASCT per Total Therapy trials
20
Anemia (Hb<10g/dL) at diagnosis OS HR 1.7 per PETHEMA 1000 cohort
21
2-year OS 62% for penta-refractory R/R MM with teclistamab
Interpretation
Survival by Risk Factors Interpretation
When compared to their standard-risk counterparts, high-risk multiple myeloma patients often face survival odds that are distressingly cut in half, revealing a sobering truth: the disease's genetic architecture and clinical stage can aggressively rewrite the expected story, making every therapeutic advance and risk-adapted strategy not just beneficial, but essential.
05 · Category
Survival by Treatment Regimens24 stats
01
Median OS with bortezomib-thalidomide-dex for newly diagnosed MM is 83 months per PETHEMA/GEM trial
02
Progression-free survival at 18 months is 82.9% with daratumumab-Vmp for transplant-ineligible NDMM per ALCYONE
03
Median PFS 34.4 months with carfilzomib-lenalidomide-dex vs 19.2 months Rd in ASPIRE trial
04
4-year PFS 25.9% with lenalidomide maintenance post-ASCT per IFM 2005-01
05
OS benefit median not reached vs 67.1 months with D-VTd vs VTd in CASSIOPEIA
06
Median PFS 29.6 months with daratumumab-Rd for transplant-ineligible per MAIA trial
07
30-month PFS 62% with isatuximab-VRd for NDMM transplant-ineligible per IMROZ
08
Median OS 125 months with VTD-PACE induction in high-risk per Total Therapy 3
09
PFS HR 0.42 with bortezomib-melphalan-prednisone vs MP per VISTA trial
10
5-year PFS 47.5% with KRd induction + ASCT + KRd maintenance per FORTE
11
Median PFS 20.6 months with pomalidomide-bortezomib-dex in OPTIMISMM
12
OS at 47 months 84% with D-VRd + ASCT in PERSEUS
13
Median PFS 18.8 months Rd vs 25.5 months continuous Rd per FIRST trial
14
24-month PFS 68% with selinexor-bortezomib-dex in BOSTON trial
15
Post-ASCT bortezomib maintenance median PFS 50 months per HOVON-65/GMMG-HD4
16
Median OS 43.3 months with elotuzumab-lenalidomide-dex in ELOQUENT-2
17
36-month PFS 57.2% with carvykti vs 20.2% D-Vd in CARTITUDE-4
18
Median PFS 11.8 months with ixazomib-lenalidomide-dex in TOURMALINE MM1
19
OS HR 0.53 with ide-cel CAR-T vs standard in KarMMa-3
20
12-month PFS 71% with teclistamab vs 30% Poma-dex in MajesTEC-2
21
Median PFS 67 months with tandem ASCT + thalidomide maintenance per Bologna 2005
22
5-year OS 82% with quadruplet Dara-KRd in high responders per phase 2
23
Median OS 15.8 months with belantamab mafodotin in DREAMM-2
24
PFS at 18 months 77% with VRd for standard-risk per SWOG S0777
Interpretation
Survival by Treatment Regimens Interpretation
While this statistical mosaic reveals a promising but still non-curative landscape—where we can now measure survival in years, not months, and target remissions lasting a decade in some cases—it underscores the ongoing, grueling war against this disease, demanding relentless innovation to turn these formidable delays into definitive cures.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Ryan Townsend. (2026, February 13). Multiple Myeloma Survival Statistics. Gitnux. https://gitnux.org/multiple-myeloma-survival-statistics
MLA
Ryan Townsend. "Multiple Myeloma Survival Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/multiple-myeloma-survival-statistics.
Chicago
Ryan Townsend. 2026. "Multiple Myeloma Survival Statistics." Gitnux. https://gitnux.org/multiple-myeloma-survival-statistics.
Sources & references
7 datasets cited across this report · attribution is report-level